Cardiovascular Disease: Gene Therapy


Recent progress in molecular and cellular biology has developed numerous effective cardiovascular drugs. However, there are still a number of diseases for which no known effective therapy exists, such as peripheral arterial disease, ischaemic heart disease and vascular bypass graft occlusion. Currently, gene therapy is emerging as a potential strategy for the treatment of cardiovascular disease to treat such diseases despite its limitation. The first human trial in cardiovascular disease was started in 1994 to treat peripheral vascular disease using vascular endothelial growth factor (VEGF). Since then, many different potent angiogenic growth factors have been tested clinically to treat peripheral arterial disease and ischaemic heart disease. Improvement of clinical symptoms in peripheral arterial disease and ischaemic heart disease has been reported. In addition, another strategy for combating disease processes is to target transcriptional process, that has been tested in a human trial.

Keywords: angiogenesis; decoy; peripheral vascular disease; VEGF; FGF

Figure 1.

Concept of therapeutic angiogenesis using DNA of angiogenic growth factors.



Alexander JH, Hafley G, Harrington RA et al. (2005) Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. Journal of American Medical Association 294: 2446–2454.

Baumgartner I, Pieczek A, Manor O et al. (1998) Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97: 1114–1123.

Comerota AJ, Throm RC, Miller KA et al. (2002) Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end‐stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. Journal of Vascular Surgery 35: 930–936.

Conte MS, Bandyk DF, Clowes AW et al. (2006) Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. Journal of Vascular Surgery 43: 742–751.

Grines CL, Watkins MW, Helmer G et al. (2002) Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105: 1291–1297.

Isner JM, Pieczek A, Schainfeld R et al. (1996) Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 348: 370–374.

Kastrup J, Jorgensen E, Ruck A et al. (2005) Direct intramyocardial plasmid vascular endothelial growth factor‐A165 gene therapy in patients with stable severe angina pectoris A randomized double‐blind placebo‐controlled study: the Euroinject One trial. Journal of the American College of Cardiology 45: 982–988.

Morishita R, Aoki M, Hashiya N et al. (2004) Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 44: 203–209.

Rajagopalan S, Mohler ER III, Lederman RJ et al. (2003) Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double‐blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108: 1933–1938.

Stewart DJ, Hilton JD, Arnold JM et al. (2006) Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Therapy 13: 1503–

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Morishita, Ryuichi(Jan 2007) Cardiovascular Disease: Gene Therapy. In: eLS. John Wiley & Sons Ltd, Chichester. [doi: 10.1002/9780470015902.a0005756.pub2]